Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.asjsur.2022.09.128 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Superficial acral fibromyxoma on the palm: a case report.
J Med Case Rep
January 2025
Department of Clinical Medicine, Jining Medical University, Jining, China.
Background: Superficial acral fibromyxoma is a noncancerous, benign tumor of soft tissue with an unidentified origin. Occurrences of abnormalities on the palm are less frequently documented.
Case Report Presentation: A 47-year-old East Asian woman presented with a palm tumor on her left knuckle that had been present for 4 months.
Superficial acral fibromyxoma with bone involvement: description and postoperative follow-up.
An Bras Dermatol
January 2025
Department of Clinical Medicine, Faculty of Medical Sciences, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Histopathologic Features of Acral Skin Biopsies in Dermatomyositis Patients and Comparison to Histopathologic Features in Non-Acral Biopsies.
J Cutan Pathol
January 2025
Department of Dermatology, Cleveland Clinic, Cleveland, Ohio, USA.
Background: Acral lesions may represent the best/only skin lesions to biopsy in patients suspected to have dermatomyositis (DM). However, histopathologic features of acral DM skin lesions are poorly characterized.
Methods: We reviewed 50 acral biopsies from 46 DM patients and assessed numerous histopathologic features.
Evaluation of Heterogeneity in the Coding Region of BRAF, MAP2K1, and MAP2K2 Genes in Primary and Metastatic Melanomas.
J Cutan Pathol
November 2024
Departament of Pathology, Federal University of São Paulo, São Paulo, Brazil.
Introduction: The incidence of melanoma has been increasing in recent decades. BRAF mutations appear in 50%-70% of melanomas. The BRAF-targeted therapy increased the disease-free survival of patients with metastatic melanoma, but this response may be short, due to several resistance mechanisms, such as the presence of other subclones with mutations.
View Article and Find Full Text PDFCutaneous melanoma in situ: a review.
Clin Exp Dermatol
October 2024
Department of Dermatology, Norfolk and Norwich University Hospital, Norwich, UK.
Cutaneous melanoma in situ (MIS), also known as 'stage 0 melanoma', is a collection of malignant melanocytes in the epidermis and epithelial adnexa, without evidence of microinvasion to the papillary dermis. Distinct histologic subtypes include lentigo maligna (LM), superficial spreading (SS) MIS and acral lentiginous (AL) MIS. LM is the most common subtype, usually diagnosed later in life (median age at diagnosis of 66-72 years) and associated with cumulative ultraviolet radiation exposure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!